Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Novel targets being explored in multiple myeloma and the value of CELMoDs

Andrew Cowan • 29 Sep 2023
IMS 2023
Multiple Myeloma Iberdomide Mezigdomide

Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, briefly discusses novel targets being explored in multiple myeloma, including FcRH5 and CD38, and further comments on the excitement surrounding the CELMoDs iberdomide and mezigdomide. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar

More from Andrew Cowan

1:24
Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs
Andrew Cowan • 29 Sep 2023
1:53
Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma
Andrew Cowan • 29 Sep 2023
1:47
Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb
Andrew Cowan • 29 Sep 2023
5:31
First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma
Andrew Cowan • 11 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals